PRPO NASDAQ
Credit Risk of going bust: higher than 53% of companies Debt: 8.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.27 (down 99%), Precipio, Inc. would be worth roughly what it owes.
Total debt $3.3M against a stock market value of $34.6M.
Distance to default 4.84 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.0M (short-term plus half of long-term), stock volatility 60.5%; Altman Z'' -13.13. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
New Haven, CT 06511
US
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Cohen David Seth | A-Award | 582 | $22.54 | 2026-10-15 |
| Valauri Christina Ri | A-Award | 122 | $22.54 | 2026-10-15 |
| Cohen David Seth | A-Award | 520 | $25.24 | 2026-07-15 |
| Valauri Christina Ri | A-Award | 108 | $25.24 | 2026-07-15 |
| Cossman Jeffrey | A-Award | 416 | $25.24 | 2026-07-15 |